Market-Moving News for July 22nd
$HEPA
$MIRA
$RR
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/28/2022 | $3.50 | Overweight | Cantor Fitzgerald |
Columbia University announced as first institution to join the program LAS VEGAS, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (NASDAQ:RR) ("Richtech Robotics"), a Nevada-based provider of AI-driven service robots, proudly announces the launch of the Richtech Accelerator Program. This initiative aims to bolster AI and robotics research at U.S. universities by integrating localized AI models with robotics hardware, marking a significant step forward in the advancement of localized AI systems for robots. The goal of this program is to provide AI and robotics research institutions with more technologically advanced development frameworks, granting them access to Richtech Robotic
Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 to promote longevity in humans and dogs through the treatment of age-related conditions, today announced the passing of Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., M.D. Out of respect and privacy for Dr. Chapman's family, details of his passing will not be made available. Telomir's Boar
Richtech Robotics' AI service robot ADAM worked alongside Delaware North at Texas Rangers' Globe Life Field LAS VEGAS, July 23, 2024 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (NASDAQ:RR) ("Richtech Robotics"), a Nevada company and a provider of AI-driven service robots, today announces the official installation of their robotic solution ADAM at the Texas Rangers' Major League Baseball stadium, Globe Life Field. With unique AI capabilities and advanced human-like motions, ADAM will serve as the first humanoid bartender robot in any major league sports arena or large-scale entertainment venue. The launch of ADAM at Globe Life Field, in collaboration with global hospitality and entertainme
SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
SC 13G - RICHTECH ROBOTICS INC. (0001963685) (Subject)
SC 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
Columbia University announced as first institution to join the program LAS VEGAS, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (NASDAQ:RR) ("Richtech Robotics"), a Nevada-based provider of AI-driven service robots, proudly announces the launch of the Richtech Accelerator Program. This initiative aims to bolster AI and robotics research at U.S. universities by integrating localized AI models with robotics hardware, marking a significant step forward in the advancement of localized AI systems for robots. The goal of this program is to provide AI and robotics research institutions with more technologically advanced development frameworks, granting them access to Richtech Robotic
Company's new ADAM-centric food and beverage brand to officially launch at Town Square location with ribbon-cutting ceremony on February 9, 2025 LAS VEGAS, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (NASDAQ:RR) ("Richtech Robotics" or the "Company"), a Nevada-based provider of AI-driven service robots, announces that the grand opening of Clouffee & Tea at Town Square, Las Vegas will take place on February 9, 2025. Clouffee & Tea is the Company's food and beverage brand centered around its AI-powered robot ADAM. This is the first store of Richtech Robotics' Clouffee & Tea brand, with additional stores expected to be open soon. With ADAM serving as barista, Clouffee & Tea at
EDISON, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, announced the launch of a "best efforts" public offering of 27,692,310 shares of common stock (or pre-funded warrants in lieu thereof) with each share of common stock (or pre-funded warrant) accompanied by (i) a series A common warrant to purchase one (1) common share at an exercise price of $0.40 per share and (ii) a series B common warrant to purchase one (1) common share at an exercise price of $0.40 per sha
- Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers and HepQuant Duo liver function test - "These findings presented today at AASLD The Liver Meeting® confirm that rencofilstat's novel mechanism of action represents a fresh approach to the treatment of severe liver disease." (Patrick Mayo, PhD, Hepion's Senior VP, Clinical Pharmacology & Analytics) EDISON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the t
EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that it expects to release additional efficacy data from the Phase 2 ALTITUDE-NASH clinical trial of its lead drug, rencofilstat, after market close on Monday, November 13, 2023. The data release will follow a late-breaker poster presentation by Hepion's Senior Vice President, Clinical Pharmacology, Patrick Mayo, PhD, at the
- Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF - - Results reinforce rencofilstat's direct antifibrotic mode of action; increases confidence for reductions in fibrosis in ongoing Phase 2b ‘ASCEND-NASH' paired biopsy trial - EDISON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence ("AI")-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced positive topline results from its recentl
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
Cantor Fitzgerald initiated coverage of Hepion Pharmaceuticals with a rating of Overweight and set a new price target of $3.50
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)
10-Q - RICHTECH ROBOTICS INC. (0001963685) (Filer)
8-K - RICHTECH ROBOTICS INC. (0001963685) (Filer)
S-3 - RICHTECH ROBOTICS INC. (0001963685) (Filer)